Mark D. Matteucci
Keine laufenden Positionen mehr
Profil
Dr. Mark D.
Matteucci is Chief Scientific Officer & SVP-Discovery Research at Threshold Pharmaceuticals, Inc.
Dr. Matteucci was previously employed as a Director-Bioorganic Chemistry by Gilead Sciences, Inc.
He received his undergraduate degree from the Massachusetts Institute of Technology and a doctorate degree from The University of Colorado.
Ehemalige bekannte Positionen von Mark D. Matteucci
| Unternehmen | Position | Ende |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.01.1999 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mark D. Matteucci
| Massachusetts Institute of Technology | Undergraduate Degree |
| The University of Colorado | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
